Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



GlaxoSmithKline Dives on Weak Growth

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

LONDON -- "Big pharma" giant GlaxoSmithKline (NYSE: GSK  ) slightly disappointed its owners today, as its latest results revealed low growth in turnover and earnings.

GSK's slow growth
As soon as GSK's first-quarter results came out at noon British Summer Time, its shares dropped vertically, taking today's decline to 40 pence.

So, why the price drop -- what spooked GSK's owners to sell their shares at first glance of these figures? Speaking as someone who has owned Glaxo shares for around 20 years, I have to say I was not impressed with its top-level growth and I also dislike its rising financial and general expenses.

Could do better
For the first quarter of 2012, GSK's turnover was 6.6 billion pounds, a 2% increase at constant exchange rates. In terms of its core businesses, operating profit was up 3% to 2 billion pounds, producing earnings per share of 27.3 pence, up 7%.

However, GSK is undergoing something of a transformation as it sells off noncore assets and restructures its research and development operations to invest for growth. Taking account of discontinued businesses and disposals, EPS was down a disappointing 10% to 26.7 pence.

Then again, GSK is a monster when it comes to generating cash. Thanks to huge sales of prescription drugs -- plus household name brands such as Aquafresh, Lucozade, Panadol, Ribena and Sensodyne -- the FTSE 100 firm generated 1 billion pounds in cash from January to March.

At first glance, GSK has a dizzying level of net debt: 8.9 billion pounds as of March 31, down from 9 billion pounds at the end of 2011. Reassuringly, this is less than 12.4% of GSK's market value, so the group is relatively lightly geared. Indeed, Sir Andrew Witty, GSK's CEO, intends to use the group's strong balance sheet and ultra-low borrowing costs to increase its debt and operational leverage.

Up goes the dividend
The thing that pleases me most about being a GSK shareholder is the clockwork regularity with which GSK increases its cash payouts to its owners. Once again, the group upped its quarterly dividend, this time by 6% to 17 pence from 16 pence. That extra penny really does mean a lot to those happy shareholders owning thousands (or even tens of thousands) of GSK shares.

In addition to hiking its dividend, GSK is to increase the amount it spends on buying back its own shares. In the first quarter, GSK spent 226 million pounds on share buybacks, but has set aside another 2 billion pounds to 2.5 billion pounds for more purchases, funding partly from selling off noncore operations.

In effect, adding together GSK's dividend yield and share buybacks, the company is offering shareholders a "dividend plus buyback" yield as high as 8.5% this year, which is a handsome return to its patient owners.

A core holding for income investors
GSK is a popular pick among fund managers seeking solid, rising dividends, including star manager Neil Woodford of Invesco Perpetual. How does it stack up value-wise today?

At its current price of 1,422.5 pence, GSK trades on a forward price-to-earnings ratio of 11.9 and offers a prospective dividend yield of 5.1%, covered a comfortable 1.6 times. This puts it on a lower rating than the FTSE 100 index, but with a dividend more than a third higher than the market as a whole.

Hence, GSK should still appeal to value seekers and dividend devotees. Indeed, I'd be happy to add to my family's holding at these levels!

We cover pharma investments -- and make specific share recommendations -- in Motley Fool Share Advisor, a premium investing service designed to help you preserve and grow your wealth. If you'd like to see for yourself how we can help, start your 30-day free trial today. There's no obligation to subscribe.

More from Cliff D'Arcy:

Cliff owns GlaxoSmithKline shares. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1870735, ~/Articles/ArticleHandler.aspx, 10/28/2016 6:42:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:02 PM
GSK $40.42 Up +0.08 +0.20%
GlaxoSmithKline CAPS Rating: ***